This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look at the approved Abbvie's Humira and the general landscape of HS treatments on the horizon
Ticker(s): ABBV, NVS, ANABWho's the expert?
Institution: Private Practice
- Board-Certified dermatologist practicing cosmetic, medical, surgical and pediatric dermatology.
- Treats about 125 HS patients/year
- Very comfortable using on label (humira) as well as off label products (Isotretinoin, IL17s, Remicade, etc).
- Served as a sub-investigator for 10 randomized clinical drug trials for atopic dermatitis, psoriasis, systemic lupus erythematosus and cutaneous T-cell lymphoma; investigator for Dupixent’s Phase 2 AD trials.
Interview GoalDiscussing the the standard of care and the competitive landscape between ABBV Humira and NVS Cosentyx, as well as the clinical studies of treatments such as ANAB imsidolimab.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
